Activating Macrophage-Mediated Cancer Immunotherapy
- 不*心
-
1 次阅读
-
0 次下载
-
2020-12-10 16:11:04
微信
赏
支付宝
文档简介:
©2020Wiley-VCHGmbH2004853(2of9)www.advmat.dewww.advancedsciencenews.comextremelyimportantinpavingthewayforclinicalapplicationofCD47-SIRPαimmunotherapy.RecentadvancesincancerimmunologyhaverevealedthatthecompromisedefficacyofCD47-SIRPαblockadesmightbecausedbyimmunosuppressivetumormicroenvironment(TME).[11,12]Inparticular,cancercellssecretcolonystimulatingfactors,whichpolarizetumor-associatedmacrophages(TAMs)towardM2phenotype.[11,12]M2TAMscanrecruitregulatoryT-cells(Tregs)tohinderCD47-blockade-inducedT-cellimmuneactivation.[2,13,14]Therefore,repolarizingTAMsfromprotu-morigenicM2phenotypetoantitumorM1onemayregaintheantitumorimmunityofCD47blockades.Moreover,thelimitedefficacyandsideeffectsmaybeowingtononspecificaccu-mulationofsystemicallyinfusedCD47antagonistsinnormaltissues.[10,12]Thus,itwouldbeidealforCD47-SIRPα-mediatedantitumorimmunotherapytoconcentrateontheTMEwhilstavoidingoff-targetimmuneactivationinothersites.Rapidprogressinnanotechnologyandmaterialsscience,espe-ciallyinfunctionaliz
评论
发表评论